Hemolytic anemia resident survival guide: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 147: Line 147:
* Avoid [[aspirin]] as it reduces the lifecycle of RBCs
* Avoid [[aspirin]] as it reduces the lifecycle of RBCs
* Vaccination against common trigger infections such as [[Hepatitis A]]& [[Hepatitis B|B]] </div>}}
* Vaccination against common trigger infections such as [[Hepatitis A]]& [[Hepatitis B|B]] </div>}}
{{familytree | | | | | | | | | | |!|,|-|-|+|-|-|.| | | | |}}
{{familytree | | | | | | | | | | |!|,|-|-|^|-|-|.| | | | |}}
{{familytree | | | | | | | | | | |!| H01 | | | H02 | |H01=<div style="float: left; text-align: Center; width: 10em; padding:1em;">'''Negative'''<br>
{{familytree | | | | | | | | | | |!| H01 | | | H02 | |H01=<div style="float: left; text-align: Center; width: 10em; padding:1em;">'''Negative'''<br>
Hereditary spherocytosis</div>|H02=<div style="float: left; text-align: left; width: 10em; padding:1em;">'''Positive'''<br>
[[Hereditary spherocytosis]]</div>|H02=<div style="float: left; text-align: left; width: 10em; padding:1em;">'''Positive'''<br>
* Autoantibodies
* Autoantibodies
* Alloimmunization
* Alloimmunization
Line 155: Line 155:
Treatment of drug induced hemolytic anemia includes removal of offending agent</div>}}
Treatment of drug induced hemolytic anemia includes removal of offending agent</div>}}
{{familytree | | | | | | | | | | |!| |!| | |,|-|^|-|.|}}
{{familytree | | | | | | | | | | |!| |!| | |,|-|^|-|.|}}
{{familytree | | | | | | | | | | |!| |!| | |!| | | I01 |I01=<div style="float: left; text-align: left; width: 10em; padding:1em;">'''Alloimmunisation treatment'''<br>
{{familytree | | | | | | | | | | |!| | I01 |!| | | | I02 |I01=<div style="float: left; text-align: left; width: 10em; padding:1em;">'''Treatment for hereditary spherocytosis'''<br>
* Currently there is no cure for hereditary spherocytosis
* Acute attacks of hemolytic anemia are treated with blood transfusions
* [[Splenectomy]] is indicated in severe cases
* Post-splenectomy, patients are vaccinated against [[influenza]], capsulated bacteria such as ''[[Streptococcus pneumoniae|S. pneumonia]]'' and [[meningococcus]]
* Cholecystectomy is indicated in patients with pigment gallstones</div>|I02=<div style="float: left; text-align: left; width: 10em; padding:1em;">'''Alloimmunisation treatment'''<br>
Causes: ABO incompatible or Rh incompatible transfusion
Causes: ABO incompatible or Rh incompatible transfusion
* Stop transfusion immediately
* Stop transfusion immediately
Line 163: Line 168:
* [[Hemodialysis]]
* [[Hemodialysis]]
* If DIC occurs then treatment with [[fresh frozen plasma]], [[platelet transfusion]] or [[cryoprecipitate]]</div>}}
* If DIC occurs then treatment with [[fresh frozen plasma]], [[platelet transfusion]] or [[cryoprecipitate]]</div>}}
{{familytree | | | | | | | | | | |!| | |,|-|^|-|-|-|.|}}
{{familytree | | | | | | | | | | |!| | J01 | | | | J02 |J01=<div style="float: left; text-align: left; width: 10em; padding:1em;">'''Warm type AIHA'''<br>
* First-line treatment: [[Corticosteroids]]
* If anemia does not improve with corticosteroids, other [[immunosuppressant]]s may be considered
* Second-line: [[Rituximab]], [[cyclophosphamide]], [[azathioprine]], [[cyclosporine]]
* Splenectomy in recurrent disease|J02=<div style="float: left; text-align: left; width: 10em; padding:1em;">'''Cold type AIHA'''<br>
* Avoid cold exposure
* [[Rituximab]] in severe or recurrent disease
* Treat underlying infection</div>}}
{{familytree | | | | | | | | | | K01 |K01=<div style="float: left; text-align: left; width: 10em; padding:1em;">'''[[Thrombotic thrombocytopenic purpura]]'''<br>
* Transfusion is '''[[contraindicated]]'''
* [[Plasmapheresis]] is treatment of choice
* [[Fresh frozen plasma]] can be given if plasmapheresis is not available
* Corticosteroids are given concomitantly
* [[Rituximab]] is emerging as a therapy when plasma exchange and corticosteroids fail
* Refractory TTP is treated with immunosuppressive agents such as [[cyclophosphamide]] and [[vincristine]]
* Caplacizumab is another treatment option but it is associated with excess bleeding
'''[[Hemolytic uremic syndrome]]'''<br>
* Treatment of HUS mainly focus on supportive care
* Steroids
* [[Hemodialysis]]
* [[Plasmapheresis]]
* Blood transfusion when necessary
'''[[Disseminated intravascular coagulation]]'''<br>
* [[Platelet]] transfusion
* [[Fresh frozen plasma]]
* [[Cryoprecipitate]]
'''[[HELLP syndrome]]'''<br>
* Immediate delivery of the baby
* Corticosteroids may be used
'''[[Malignant hypertension]]'''
* Careful lowering of mean arterial pressure over 8 hours
* Parenteral antihypertensive agents such as [[labetalol]], [[nicardipine]], [[sodium nitroprusside]] etc
'''[[Paroxysmal nocturnal hemoglobinuria]]'''<br>
* Blood transfusions in severe anemia
* Prevention of [[thrombosis]] with [[warfarin]]
* [[Eculizumab]] </div>}}
{{familytree/end}}
{{familytree/end}}



Revision as of 14:58, 5 August 2020

Hemolytic anemia
Resident Survival Guide
Overview
Causes
FIRE
Diagnosis
Treatment
Do's
Don'ts


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];

Overview

Causes

Life threatening causes

Other causes

For a complete list of hemolytic anemia causes click here

Diagnosis

The approach to diagnosis of hemolytic anemia is based on a step-wise testing strategy. Below is an algorithm summarising the identification and laboratory diagnosis of hemolytic anemia.

 
 
 
 
 
 
 
 
 
 
 
 
Characterize the symptoms:
Weakness
Shortness of breath
Jaundice
Lethargy
Chest pain and reduced exercise tolerance
Pica
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Examine the patient:
Tachypnea
❑ Cold and clammy skin
Hypotension
❑ HEENT signs:


❑ Cardiovascular exam:


❑ Abdominal exam:


❑ Skin exam:

  • Pallor of nail beds, palmar creases
  • Bronze skin colour in case of repeated transfusions
  • Leg ulcers

Fever and neurological signs are seen in TTP
Hemoglobinuria in some cases
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Initial workup for hemolysis:
❑ Indirect bilirubin
❑ serum haptoglobin
Lactate dehydrogenase level
Reticulocyte count
Urinalysis
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No laboratory evidence of hemolysis
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Degmacytes
 
Normal cell morphology
 
Spherocytes
 
Elliptocytes
 
Shistocytes
 
Sickle shaped cells
 
Hypochromic, microcytic cells
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
G6PD deficiency
 
Family history
❑ Drug history
❑ Recent infections
 
 
 
 
 
 
 
 
Sickle cell disease
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
H/o exercise, exertion, trauma or surgery?
 
 
 
 
 
Beta thalassemia
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Negative
 
Positive
 
No
 
Yes
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CD55/59
 
❑ Drug induced hemolytic anemia
❑ Autoimmune disease
 
❑Exercise induced hemolysis
Prosthetic heart valve
❑Severe aortic stenosis
 
Microangiopathic hemolytic anemia
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Positive
 
 
 
Negative
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pre-eclampsia and eclampsia
 
Recent diarrhea
 
 
Decreased ADAMTS13 activity
 
 
 
 
 
Paroxysmal nocturnal hemoglobinuria
 
 
 
Hereditary spherocytosis
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HELLP syndrome
 
Hemolytic uremic syndrome
 
 
Thrombotic thrombocytopenic purpura
 

Treatment

  • The treatment of hemolytic anemia depends on the cause of anemia.[5][6][7]
  • Treatment plan is summarized in the algorithm below based on the 2017 guidelines published by the British Society of Hematology and[8] and the 2020 recommendations by the First International Consensus Group.[9]
 
 
 
 
 
 
 
 
 
 
 
 
 
History
  • Fatigue
  • Dyspnea
  • Lightheadedness

Physical examination

  • Pallor
  • Icterus
  • Cold, clammy skin
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Peripheral blood smear findings
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bite cells
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Oxidative stress like
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Treatment of acute attacks
  • Blood transfusion
  • Hemodialysis
  • Long term measures

    • Avoidance of trigger foods and drugs
    • Splenectomy- spleen is the site of destruction of RBCs
    • Avoid aspirin as it reduces the lifecycle of RBCs
    • Vaccination against common trigger infections such as Hepatitis A& B
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
    Positive
    • Autoantibodies
    • Alloimmunization
    • Drug-induced
    Treatment of drug induced hemolytic anemia includes removal of offending agent
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
    Treatment for hereditary spherocytosis
    • Currently there is no cure for hereditary spherocytosis
    • Acute attacks of hemolytic anemia are treated with blood transfusions
    • Splenectomy is indicated in severe cases
    • Post-splenectomy, patients are vaccinated against influenza, capsulated bacteria such as S. pneumonia and meningococcus
    • Cholecystectomy is indicated in patients with pigment gallstones
     
     
     
     
     
    Alloimmunisation treatment

    Causes: ABO incompatible or Rh incompatible transfusion

     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
    Warm type AIHA
     
     
     
    Cold type AIHA
  • Avoid cold exposure
  • Rituximab in severe or recurrent disease
  • Treat underlying infection
  •  
     
     
     
     
     
     
     
     
    Thrombotic thrombocytopenic purpura
    • Transfusion is contraindicated
    • Plasmapheresis is treatment of choice
    • Fresh frozen plasma can be given if plasmapheresis is not available
    • Corticosteroids are given concomitantly
    • Rituximab is emerging as a therapy when plasma exchange and corticosteroids fail
    • Refractory TTP is treated with immunosuppressive agents such as cyclophosphamide and vincristine
    • Caplacizumab is another treatment option but it is associated with excess bleeding

    Hemolytic uremic syndrome

    Disseminated intravascular coagulation

    HELLP syndrome

    • Immediate delivery of the baby
    • Corticosteroids may be used

    Malignant hypertension

    Paroxysmal nocturnal hemoglobinuria

    Do's

    Don'ts

    References

    1. Phillips J, Henderson AC (2018). "Hemolytic Anemia: Evaluation and Differential Diagnosis". Am Fam Physician. 98 (6): 354–361. PMID 30215915.
    2. Renard D, Rosselet A (2017). "Drug-induced hemolytic anemia: Pharmacological aspects". Transfus Clin Biol. 24 (3): 110–114. doi:10.1016/j.tracli.2017.05.013. PMID 28648734.
    3. Morishita E (2015). "[Diagnosis and treatment of microangiopathic hemolytic anemia]". Rinsho Ketsueki. 56 (7): 795–806. doi:10.11406/rinketsu.56.795. PMID 26251142.
    4. Barcellini W, Bianchi P, Fermo E, Imperiali FG, Marcello AP, Vercellati C; et al. (2011). "Hereditary red cell membrane defects: diagnostic and clinical aspects". Blood Transfus. 9 (3): 274–7. doi:10.2450/2011.0086-10. PMC 3136593. PMID 21251470.
    5. Matsumoto M, Fujimura Y, Wada H, Kokame K, Miyakawa Y, Ueda Y; et al. (2017). "Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) 2017 in Japan". Int J Hematol. 106 (1): 3–15. doi:10.1007/s12185-017-2264-7. PMID 28550351.
    6. Bagga A, Khandelwal P, Mishra K, Thergaonkar R, Vasudevan A, Sharma J; et al. (2019). "Hemolytic uremic syndrome in a developing country: Consensus guidelines". Pediatr Nephrol. 34 (8): 1465–1482. doi:10.1007/s00467-019-04233-7. PMID 30989342.
    7. Yawn BP, Buchanan GR, Afenyi-Annan AN, Ballas SK, Hassell KL, James AH; et al. (2014). "Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members". JAMA. 312 (10): 1033–48. doi:10.1001/jama.2014.10517. PMID 25203083.
    8. Kamesaki T (2019). "[Progress in diagnosis and treatment of autoimmune hemolytic anemia]". Rinsho Ketsueki. 60 (9): 1100–1107. doi:10.11406/rinketsu.60.1100. PMID 31597833.
    9. Jäger U, Barcellini W, Broome CM, Gertz MA, Hill A, Hill QA; et al. (2020). "Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting". Blood Rev. 41: 100648. doi:10.1016/j.blre.2019.100648. PMID 31839434.